Company Analysis Dr. Reddy's Laboratories Limited
1. Summary
Advantages
- Price (1354.2 βΉ) is less than fair price (4397.48 βΉ)
- Current debt level 4.26% is below 100% and has decreased over 5 years from 14.94%.
- The company's current efficiency (ROE=21.69%) is higher than the sector average (ROE=3.69%)
Disadvantages
- Dividends (0.126%) are below the sector average (0.6496%).
- The stock's return over the last year (-76.93%) is lower than the sector average (-42.81%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
Dr. Reddy's Laboratories Limited | Healthcare | Index | |
---|---|---|---|
7 days | -1.2% | -6.2% | -0.6% |
90 days | -79.8% | -5.6% | -4.8% |
1 year | -76.9% | -42.8% | 7.2% |
DRREDDY vs Sector: Dr. Reddy's Laboratories Limited has significantly underperformed the "Healthcare" sector by -34.12% over the past year.
DRREDDY vs Market: Dr. Reddy's Laboratories Limited has significantly underperformed the market by -84.15% over the past year.
Slightly volatile price: DRREDDY is more volatile than the rest of the market on "Bombay Stock Exchange" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: DRREDDY with weekly volatility of -1.48% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1354.2 βΉ) is lower than the fair price (4397.48 βΉ).
Price significantly below the fair price: The current price (1354.2 βΉ) is 224.7% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (18.55) is lower than that of the sector as a whole (56.11).
P/E vs Market: The company's P/E (18.55) is lower than that of the market as a whole (43.66).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.68) is lower than that of the sector as a whole (8.08).
P/BV vs Market: The company's P/BV (3.68) is lower than that of the market as a whole (6.15).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.7) is lower than that of the sector as a whole (17.79).
P/S vs Market: The company's P/S indicator (3.7) is lower than that of the market as a whole (8.67).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (10.41) is higher than that of the sector as a whole (4.22).
EV/Ebitda vs Market: The company's EV/Ebitda (10.41) is lower than that of the market as a whole (15.13).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 34.97% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (34.97%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-17.15%).
5.4. ROE
ROE vs Sector: The company's ROE (21.69%) is higher than that of the sector as a whole (3.69%).
ROE vs Market: The company's ROE (21.69%) is higher than that of the market as a whole (-0.3088%).
5.5. ROA
ROA vs Sector: The company's ROA (15.68%) is higher than that of the sector as a whole (3.44%).
ROA vs Market: The company's ROA (15.68%) is higher than that of the market as a whole (7.53%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (21.41%) is higher than that of the sector as a whole (11.26%).
ROIC vs Market: The company's ROIC (21.41%) is higher than that of the market as a whole (16.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.126% is below the average for the sector '0.6496%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.126% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 0.126% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (11.94%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription